@nationglass9
Active 8 months, 3 weeks ago
The drug may enhance hypoglycemic agents by slowing their clearance, heightening the risk of symptomatic hypoglycemia in insulin- or sulfonylurea-treated patients. Clinically consequential interactions center on hepatic enzyme modulation and additive physiologic effects. Additional absolute contraindications include nephrosis, the nephrotic […] View
-
Pope Mason posted an update 8 months, 3 weeks ago
The drug may enhance hypoglycemic agents by slowing their clearance, heightening the risk of symptomatic hypoglycemia in insulin- or sulfonylurea-treated patients. Clinically consequential interactions center on hepatic enzyme modulation and additive physiologic effects. Additional absolute contraindications include nephrosis, the nephrotic phase…[Read more]
-
Pope Mason became a registered member 8 months, 3 weeks ago
